Pharmaceutical composition with anti-diabetic action

A method for the treatment or prophylaxis of diabetes, comprising administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a compound of general formula (I):

• where:
• R1 is selected from the group consisting of an optionally substituted alkyl, an optionally substituted oxyalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclil, and an optionally substituted aryl, wherein the optional substituent(s) may be one or more members selected from lower alkyl, halogen, oxyalkyl, hydroxyl, and amino;
• R2 is —H, or —CH2NR′R″;
• where R′ and R″, independently of each other, are each selected from the group consisting of hydrogen, optionally substituted alkene, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocyclil, and optionally substituted aryl, or where R′ and R″, along with the nitrogen atom with which they are bound, form guanidyl or optionally substituted azaheterocyclil;
• R3 is an alkoxy group, or —OH;
• or R2 and R3 form together an optionally substituted oxazine cycle;
• R4 is selected from the group consisting of hydrogen, halogen, cyano, NO2, trifluoromethyl, optionally substituted aryl and optionally substituted heterocyclil;
• A represents —S—, —SO—, —SO2—, and n=0-1;
• B represents —(CH2)k—R5, where k=0-2, and where R5 is an optionally substituted aryl, an optionally substituted alkyl, an optionally substituted oxyalkyl, or an optionally substituted heterocyclil, or where R5 represents a substituent of the type:
• where Rn1 and Rn2 are defined according to the definitions of the substituents R′ and R″above;
• or hydrates and/or pharmaceutically acceptable salts thereof.

A method of preparing a pharmaceutical composition effective for treating diabetes, comprising formulating a compound of general formula I with one or more pharmaceutically acceptable carriers or excipients;

• wherein said compound of general formula (I) is:
• where:
• R1 is selected from the group consisting of an optionally substituted alkyl, an optionally substituted oxyalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclil, and an optionally substituted aryl, wherein the optional substituent(s) may be one or more members selected from lower alkyl, halogen, oxyalkyl, hydroxyl, and amino;
• R2 is —H or —CH2NR′R″, where R′ and R″, independently of each other, are each selected from the group consisting of hydrogen, optionally substituted alkene, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted heterocyclil, and optionally substituted aryl, or where R′ and R″, along with the nitrogen atom with which they are bound, form guanidyl or optionally substituted azaheterocyclil;
• R3 is an alkoxy group or —OH;
• or where R2 and R3 form together an optionally substituted oxazine cycle;
• R4 is selected from the group consisting of hydrogen, halogen, cyano, NO2, trifluoromethyl, optionally substituted aryl and optionally substituted heterocyclil;
• A represents —S—, —SO—, —SO2—, and n=0-1;
• B represents —(CH2)k—R5, where k=0-2, and where R5 is an optionally substituted aryl, an optionally substituted alkyl, an optionally substituted oxyalkyl, or an optionally substituted heterocyclil, or where R5 represents a substituent of the type:
• where Rn1 and Rn2 are defined according to the definitions of the substituents R′ and R″ above;
• or hydrates and/or pharmaceutically acceptable salts thereof.